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SUMMARY
Background
Idiosyncratic drug-induced liver injury (DILI) is a complex disorder that is dif-
ﬁcult to predict, diagnose and treat.
Aim
To describe the global serum proteome of patients with DILI and controls.
Methods
A label-free, mass spectrometry-based quantitative proteomic approach was
used to explore protein expression in serum samples from 74 DILI patients
(collected within 14 days of DILI onset) and 40 controls. A longitudinal analy-
sis was conducted in a subset of 21 DILI patients with available 6-month fol-
low-up serum samples.
Results
Comparison of DILI patients based on pattern, severity and causality assessment
of liver injury revealed many differentially expressed priority 1 proteins among
groups. Expression of fumarylacetoacetase was correlated with alanine amino-
transferase (ALT; r = 0.237; P = 0.047), aspartate aminotransferase (AST;
r = 0.389; P = 0.001) and alkaline phosphatase (r = 0.240; P = 0.043), and
this was the only protein with signiﬁcant differential expression when compar-
ing patients with hepatocellular vs. cholestatic or mixed injury. In the longitudi-
nal analysis, expression of 53 priority 1 proteins changed signiﬁcantly from
onset of DILI to 6-month follow-up, and nearly all proteins returned to expres-
sion levels comparable to control subjects. Ninety-two serum priority 1 proteins
with signiﬁcant differential expression were identiﬁed when comparing the DILI
and control groups. Pattern analysis revealed proteins that are components of
inﬂammation, immune system activation and several hepatotoxicity-speciﬁc
pathways. Apolipoprotein E expression had the greatest power to differentiate
DILI patients from controls (89% correct classiﬁcation; AUROC = 0.97).
Conclusion
This proteomic analysis identiﬁed differentially expressed proteins that are
components of pathways previously implicated in the pathogenesis of idiosyn-
cratic drug-induced liver injury.
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INTRODUCTION
Although relatively rare with the majority of approved
medications, idiosyncratic drug-induced liver injury
(DILI) is an increasingly common event due to ever-
expanding use of prescription medications. DILI is the
most frequent adverse drug reaction that results in ter-
mination of new drug development programmes, failure
of approval by regulatory agencies, or withdrawal of
approved medications.1–4 When idiosyncratic DILI does
occur it can be a serious clinical event and, in fact,
accounts for up to 13% of acute liver failure cases in the
United States.5–7 Despite the large impact DILI has on
both patient health and the development of important
new medications, there is little understanding of the risk
factors and pathogenesis of idiosyncratic ADRs that
result in liver injury.8, 9 This lack of understanding has
prevented development of new clinical tests that are
needed to aid in diagnosis and management of DILI.
Worldwide, several multicenter networks have been
established to aid in the study of identiﬁcation, causes
and prevention of idiosyncratic DILI. In the United
States, the Drug-Induced Liver Injury Network (DILIN)
was founded in 2003 as a collaborative effort among the
National Institutes of Health, eight academic clinical cen-
tres, and a data coordinating centre.10 One component is
the DILIN Prospective Study, which is a prospective
observational study of patients with suspected DILI. This
study is described in several publications reporting study
design,10 causality assessment,11 implicated medications,
clinical features and outcomes for the ﬁrst 300 enrolled
patients,12 and clinical characteristics of drug-speciﬁc
hepatotoxicity.13, 14
Here, we utilised a label-free quantitative proteomics
approach (LFQP) to proﬁle global protein expression in
serum samples from patients with idiosyncratic DILI
enrolled in the DILIN prospective study and healthy
control subjects. LFQP is a high-throughput, sensitive
method for quantiﬁcation of thousands of proteins in
complex biological samples, including serum.15 The
objectives of this study were to: (i) describe differences
in serum protein expression among DILI patients based
on hepatocellular, cholestatic, or mixed pattern of liver
injury, severity of liver injury (mild, moderate or severe/
fatal), and causality assessment (deﬁnite, very likely,
probable, possible or unlikely), (ii) explore longitudinal
changes in serum protein expression over a 6-month
recovery period in a subset of DILI patients, (iii) identify
differentially expressed serum proteins among patients
with DILI vs. controls, (iv) identify potential protein bio-
markers of DILI with high discriminate ability and (v)
compare differentially expressed proteins identiﬁed in
the current DILI study to those identiﬁed in our previ-
ous serum proteomic analysis of patients across the spec-
trum of nonalcoholic fatty liver disease (NAFLD).16
MATERIALS AND METHODS
Serum samples were obtained from a local blood bank
(healthy controls) or were collected as part of the DILIN
prospective study, which was approved by the Institu-
tional Review Board at each academic clinical centre. As
described,10 eligible patients with suspected DILI pro-
vided written informed consent prior to their baseline
study visit in which all previous medical data was
reviewed with regard to inclusion/exclusion criteria and
a complete history and physical examination were per-
formed. Patients were then enrolled if there was strong
suspicion that liver injury was caused by a prescription
or over-the-counter medication or dietary supplement/
herbal product within the previous 6 months. Further
laboratory testing and data collection were also under-
taken to fully characterise the DILI event and to exclude
underlying or competing aetiologies. All surviving partic-
ipants were invited to return for a 6-month follow-up
visit.
Inclusion/exclusion criteria
Eligibility for the DILIN prospective study included
>2 years of age, a date of DILI onset within the
6 months prior to enrolment and satisfaction of at least
one of the following biochemical criteria: (i) serum ala-
nine aminotransferase (ALT) or aspartate aminotransfer-
ase (AST) >5 times the upper limit of normal (ULN) or
alkaline phosphatase >2 times the ULN (or increases
above pre-treatment baselines if liver biochemistries were
elevated prior to starting drug) on two consecutive occa-
sions at least 2 days apart, (ii) total serum bilirubin
>2.5 mg/dL together with elevated AST, ALT or alkaline
phosphatase or (iii) international normalised ratio (INR)
>1.5 together with elevated AST, ALT or alkaline phos-
phatase. Patients with pre-existing liver conditions who
developed superimposed DILI were included. Patients
with known or suspected acetaminophen toxicity or
prior liver or bone marrow transplant were excluded.
Clinical characterization of DILI and causality
assessment
Type of liver injury was characterised by the R ratio
[R = (ALT/ULN)/(alkaline phosphatase/ULN)]1, 2: (i)
R  5 was characterised as hepatocellular DILI, (ii)
R  2 was characterised as cholestatic DILI and (iii)
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R > 2 to R < 5 was characterised as mixed DILI. As pre-
viously described,10 severity of DILI was graded as: (i)
mild, (ii) moderate, (iii) moderate-hospitalised, (iv)
severe or (v) fatal. For the purposes of this study,
patients with moderate or moderate-hospitalised DILI
were combined (moderate DILI) and patients with severe
or fatal DILI were combined (severe/fatal DILI). Causal-
ity was assessed by two different methods as previously
described10–12: (i) the Roussel Uclaf Causality Assessment
Method (RUCAM) and (ii) assignment of DILIN causal-
ity score based on unanimous consensus of at least three
DILIN Causality Committee members. Final causality
was categorised as: (i) deﬁnite (>95% likelihood), (ii)
very likely (75–95%), (iii) probable (50–74%), (iv) possi-
ble (25–49%) or (v) unlikely (<25%).
Sample preparation
All proteomic analyses were performed by the Protein
Analysis Research Centre at Indiana University School of
Medicine. As previously described,15 samples were trea-
ted with protease inhibitor cocktail (Sigma Aldrich, St.
Louis, MO, USA) and protein extraction from <100 lL
serum was carried out in lysis buffer containing 8M urea
and 10 mM dithiothreitol (DTT). Fourteen high-abun-
dance proteins were depleted by SepproTip columns
(albumin, IgG, alpha-1-antitrypsin, IgA, IgM, transferrin,
haptoglobin, alpha-2-macroglobulin, ﬁbrinogen, comple-
ment C3, alpha-1-acid glycoprotein and apolipoproteins
A-1, A-II and B) and Bradford assay was used to deter-
mine protein concentrations.17 DTT, iodoacetamide, tri-
ethylphosphine and iodoethanol were used to reduce and
alkylate resulting protein extracts.18 Protein mixtures
were digested with trypsin and ﬁltered through spin ﬁl-
ters before being applied to the high-performance liquid
chromatography (HPLC) system. Stability of the HPLC
system and mass spectrometry (MS) instrument was
evaluated by spiking a constant amount of chicken lyso-
zyme as an internal reference prior to tryptic digestion
of protein extracts.
Liquid chromatography-tandem mass spectrometry
(LC/MS/MS)
In random order, peptides (<20 lg) were injected onto
an Agilent 1100 nano-HPLC system (Agilent Technolo-
gies, Inc., Santa Clara, CA, USA) equipped with a C18
capillary column. Peptides were eluted with a linear gra-
dient from 5% to 45% acetonitrile developed at a ﬂow
rate of 500 nL/min over 120 min. Efﬂuent was electro-
sprayed into a LTQ mass spectrometer (Thermo Fisher
Scientiﬁc, Inc., Waltham, MA, USA). Acquired data
were ﬁltered and analysed by a proprietary algorithm19
and database searches were carried out using the X!Tan-
dem 20 and SEQUEST21 algorithms against the Interna-
tional Protein Index (IPI) human database (European
Bioinformatics Institute, version 3.60) as previously
described.22
Protein identiﬁcation and quantiﬁcation
Proteins were classiﬁed as priority one through four
according to quality of peptide identiﬁcation (ID). ID
conﬁdence for each protein is greater with: (i) higher ID
conﬁdence of individual peptides and (ii) a greater num-
ber of distinct amino acid sequences identiﬁed. Priority 1
proteins have the greatest likelihood of correct identiﬁca-
tion (with multiple unique peptide sequences identiﬁed)
and priority 4 proteins have the least likelihood of cor-
rect identiﬁcation.
Quantiﬁcation of proteins was carried out as previ-
ously described.19 Brieﬂy, raw data ﬁles were acquired
from the MS instrument and all chromatograms were
aligned according to their retention time. After align-
ment, the area-under-the-curve for each individually
aligned peak was measured, normalised and compared
for relative abundance.
Biostatistical analysis
Signiﬁcant changes in protein expression among groups
were detected by ANOVA (analysis of variance). All data
were normalised on a log2 scale (one unit difference is
equivalent to a two-fold change).23
From the ANOVA model a P-value, an estimate of the
FPR (false positive rate), was obtained. The P-value was
modiﬁed to a q-value, which estimates the FDR (false
discovery rate). The q-value threshold was ﬁxed to con-
trol the FDR at 5% (<0.05). A protein with ‘signiﬁcant
change’ or ‘differential expression’ was deﬁned as a dif-
ference in protein expression between any two groups
with a q-value <0.05.
Pathway and additional statistical analyses
For the main analysis and all subgroup analyses, all pri-
ority 1 proteins with signiﬁcant differential expression
(q < 0.05) were considered for further characterization.
Identiﬁed proteins were classiﬁed according to biological
function(s) using Ingenuity Pathway Analysis software
(https://analysis.ingenuity.com). Pearson’s correlation
coefﬁcient was used to detect associations between liver
biochemistries and expression of priority 1 proteins.
When appropriate, stepwise regression analysis was per-
formed to take into account multiple independent vari-
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ables (proteins) predicting the dependent variable (liver
biochemistries). Linear discriminant analysis and area-
under-the-receiver-operating-curve (AUROC) was used
to determine the ability of individual proteins differen-
tially expressed between groups and patient characteris-
tics to predict the presence of DILI vs. controls.
Statistical analyses were performed using JMP software
(SAS Institute, Inc., Cary, NC, USA). A P-value <0.05
was considered signiﬁcant.
RESULTS
Patient characteristics
A total of 114 subjects were included in this serum pro-
teomic study. Characteristics of the 74 DILI patients
(with a serum sample collected within 14 days of DILI
onset) and 40 control subjects, including demographics
and liver biochemistries, are shown in Table 1. Impli-
cated agents, regardless of causality assessment, are listed
in Table 2. Overall, 2671 proteins were identiﬁed with
the criteria we set for LFQP19, 22: 217 priority 1 proteins,
734 priority 2 proteins, 182 priority 3 proteins and 1538
priority 4 proteins.
In the DILI cohort, correlations between expression
of differentially expressed priority 1 proteins and liver
biochemistries were explored (Table 3). Interestingly,
expression of fumarylacetoacetase, an enzyme required
for the breakdown of tyrosine, was associated with ALT
(r = 0.237; P = 0.047), AST (r = 0.389; P = 0.001) and
alkaline phosphatase (r = 0.240; P = 0.043). Fructose-
bisphosphate aldolase B, a protein involved in carbohy-
drate metabolism, was identiﬁed as an independent
predictor of both ALT (r = 0.391; P = 0.001) and AST
(r = 0.523; P < 0.001). Apolipoproteins C-III (compo-
nent of VLDL) and A-II (component of HDL) were
independently associated with alkaline phosphatase
(r = 0.275; P = 0.014) and bilirubin (r = 0.225;
P = 0.05) levels respectively. Additional independent
predictors of bilirubin included proteins involved in
extracellular matrix structure [extracellular matrix pro-
tein 1 (isoform 1) (r = 0.229; P = 0.024)], iron metabo-
lism and antioxidant function [hemopexin (r = 0.494;
P < 0.001)], and post-translational protein modiﬁcation
[E3 SUMO-protein ligase RanBP2 (r = 0.265;
P = 0.024)].
Pattern analysis: comparison of hepatocellular,
cholestatic, or mixed liver injury
Within the DILI cohort, 45 patients (61%) were classiﬁed
as having hepatocellular DILI, 15 patients (20%) had
Table 1 | Clinical characteristics and liver
biochemistries of all study participants
DILI cohort
n = 74
Healthy
controls
n = 40
Age, mean ± s.d. (years) 47.8 ± 18.3 49.2 ± 13.1
Female (%) 53 28
Self-reported race (%)
White 72 95
Black 11 5
Others 16 0
Unknown 1 0
Body mass index,
mean ± s.d. (kg/m2)
27.0 ± 6.6 30.5 ± 6.9
Alcohol use (%) 39
Preexisting liver
disease (%)*
8
Prior drug allergies (%) 50
Diabetes mellitus (%) 34
Liver biochemistries, mean ± s.d.
ALT (U/L) 1086 ± 1409 17.4 ± 5.1
AST (U/L) 1028 ± 1274 24.3 ± 4.9
Alkaline phosphatase
(U/L)
325.3 ± 470.1 63.2 ± 14.0
Total bilirubin (mg/dL) 8.0 ± 7.6 0.6 ± 0.2
INR 1.8 ± 1.2
Absolute eosinophils/lL
(mean ± s.d.)
172.3 ± 240.2
Pattern of liver injury (%)
Hepatocellular 61
Cholestatic 20
Mixed 15
Unknown 4
Severity of liver injury (%)
Mild 12
Moderate 47
Severe/fatal 26
Unknown 15
Causality score (%)
Deﬁnite 23
Very likely 36
Probable 11
Possible 15
Unknown 15
Implicated agents (%)
Single prescribed agent 57
Single dietary agent 5
Multiple prescribed
agents
35
Unknown 3
Chronic DILI (%) 5
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cholestatic DILI, 11 patients (15%) had mixed DILI and
three patients (4%) were not classiﬁed by DILI type and
were therefore not included in the pattern analysis. We
identiﬁed 25 differentially expressed (q < 0.05) proteins
when comparing patients with hepatocellular and chole-
static patterns of DILI (listed in Supplementary Table
S1). Expression of only one protein, fumarylacetoacetase,
was different among patients with hepatocellular and
mixed DILI, and there were no differentially expressed
proteins when comparing the cholestatic and mixed DILI
groups. Pattern analysis of the 25 priority 1 proteins dif-
ferentially expressed between hepatocellular and chole-
static DILI patterns showed involvement in mechanistic
pathways implicated in DILI, including hepatotoxicity-
speciﬁc mechanisms of liver proliferation and develop-
ment of cirrhosis (Figure 1).
Severity analysis: comparison of mild, moderate or
severe/fatal liver injury
Mild (n = 9; 12%), moderate (n = 35; 47%) and severe/
fatal (n = 19; 26%) DILI were all well-represented in our
cohort. Severity of DILI was not reported for 11 patients
(15%), and these subjects were excluded from this sever-
ity analysis. As shown in Supplementary Table S2,
expression of 29 priority 1 proteins was signiﬁcantly dif-
ferent (q < 0.05) between the mild and moderate DILI
groups, 52 priority 1 proteins were differentially
expressed between the mild and severe/fatal DILI
patients, and comparison of the moderate vs. severe/fatal
DILI groups revealed 23 priority 1 proteins with signiﬁ-
cant differential expression. Expression of 9 priority 1
proteins was signiﬁcantly different when comparing all
three severity groups: obscurin (isoform 1), polymeric
immunoglobulin receptor, serine/threonine-protein
kinase 10, apolipoprotein A-II, transthyretin, macrophage
Table 1 | (Continued)
DILI cohort
n = 74
Healthy
controls
n = 40
Liver-related mortality (%) 5
Liver transplantation (%) 0
ALT, alanine aminotransferase; AST, aspartate aminotransfer-
ase; DILI, drug-induced liver injury; INR, international norma-
lised ratio; s.d., standard deviation.
* Pre-existing liver conditions included hepatitis C, hepatitis B,
alcoholic liver disease and nonalcoholic fatty liver disease.
Table 2 | Implicated causative agents
Single agent
Multiple agents
(n = 1 case each)
Isoniazid (n = 5) Moxiﬂoxacin + ciproﬂoxacin
+ amoxicillin/clavulanate
Herbal preparation (n = 5) Pregabalin + simvastatin
+ mercaptopurine
Amoxicillin/
clavulanate (n = 3)
Darunavir
+ abacavir/lamivudine
+ didanosine
Nitrofurantoin (n = 3) Trimethoprim-
sulfamethoxazole
+ orlistat
Methyldopa (n = 2) Metoprolol + diltiazem
+ alprazolam
Minocycline (n = 2) Isoﬂurane + lorazepam
+ clindamycin
Trimethoprim-
sulfamethoxazole (n = 2)
Trimethoprim-
sulfamethoxazole +
tetracycline
Amiodarone (n = 1) Phenytoin + levoﬂoxacin
+ phenobarbital
Amlodipine (n = 1) Isoniazid + rifampicin
Anabolic steroid (n = 1) Ciproﬂoxacin + metronidazole
Antithymocite
immunoglobulin (n = 1)
Amitriptyline + nicotinic acid
Atorvastatin (n = 1) Allopurinol + rosiglitazone
Atripla (n = 1) Vincristine + asparaginase
Azathioprine (n = 1) Ceftriaxone + ampicillin/
sulbactam + ﬂuconazole
Azithromycin (n = 1) Flavocoxid + pregabalin
Bortezomib (n = 1) Amoxicillin/clavulanate
+ valproic acid + amiodarone
Chlorzoxazone (n = 1) Methyldopa + labetalol
Drospirenone/
ethinylestradiol (n = 1)
Dicloxacillin +
amoxicillin/clavulanate
Duloxetine (n = 1) Nicotinic acid + neomycin
Fenoﬁbrate (n = 1) Lamotrigine + ziprasidone
Investigational drug (n = 1) Lamotrigine + valproic acid
Lamotrigine (n = 1) Disulﬁram + lisinopril
Nicotinic Acid (n = 1) Allopurinol + ﬂuconazole
+ cyclophosphamide
Octreotide (n = 1) Carbamazapine + bactrim
+ lisinopril
Oxacillin (n = 1) Metformin + fenoﬁbrate
Phenylpropanolamine (n = 1) Voriconazole + ﬂuconazole
Phenytoin (n = 1)
Pregabalin (n = 1)
Rifabutin (n = 1)
Sertraline (n = 1)
Simvastatin (n = 1)
Telithromycin (n = 1)
Valaciclovir (n = 1)
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colony-stimulating factor 1 receptor, complement com-
ponent C7, vitamin D-binding protein and vitamin
D-binding protein precursor. Pattern analysis of these
nine common proteins revealed involvement in the acute
phase response, activation of the complement cascade
and peroxisome proliferator-activated receptor (PPAR)-a,
and association with development of hepatocellular
carcinoma.
Causality assessment analysis: comparison of
deﬁnite, very likely, probable, possible or unlikely
DILI
In our cohort of DILI patients, 17 were adjudicated as
deﬁnite DILI (23%), 27 as very likely DILI (36%), 8 as
probable DILI (11%) and 11 as possible DILI (15%).
Causality assessment was not completed in seven cases
(9%), and those patients were excluded from this causal-
ity assessment analysis. Signiﬁcant differential expression
of priority 1 proteins was only observed when comparing
the deﬁnite and possible DILI groups (list of 12 proteins
is shown in Supplementary Table S3). Four subjects were
deemed unlikely to have DILI and were therefore classi-
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Figure 1 | Pathway analysis of priority 1 proteins with
signiﬁcant differential expression when comparing DILI
patients with hepatocellular and cholestatic patterns of
liver injury. Classiﬁcation of the 25 priority 1 proteins
with signiﬁcant (q < 0.05) differential expression when
comparing patients with hepatocellular and cholestatic
DILI demonstrated involvement in inﬂammatory and
immune system response pathways, activation of the
coagulation cascade and included proteins previously
implicated in liver proliferation and development of
cirrhosis.
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ﬁed as an ‘acute liver disease group.’ When these four
patients were compared with patients with DILI, no dif-
ferentially expressed priority 1 proteins were identiﬁed.
Longitudinal DILI analysis
Serum samples obtained within 14 days of DILI onset
and after a 6-month follow-up period were available for
a subset of patients (n = 21; 28% of the DILI cohort),
and clinical characteristics and liver biochemistries of
these patients are shown in Table 4. Expression of 53
priority 1 proteins changed signiﬁcantly (q < 0.05) over
the 6-month follow-up period (Supplementary Table S4),
and nearly all proteins trended back towards a ‘normal’
expression level (utilising the control group as a
reference standard). As shown in Figure 2, pathway anal-
ysis of these 53 proteins again revealed involvement in
host immune response, oxidative stress and hepatotoxic-
ity-speciﬁc pathways including liver inﬂammation, stea-
tosis/steatohepatitis, necrosis/cell death and hepatitis.
Comparison of DILI patients and controls
Ninety-two priority 1 proteins were found to be differen-
tially expressed (q < 0.05) between the DILI and control
groups (described in Supplementary Table S5). Pattern
analysis of these proteins revealed components of several
mechanistic pathways, including inﬂammation, acute
phase proteins, complement system activation and coag-
ulation (Figure 3; Panel A). In addition, several pathways
directly related to hepatotoxicity (hepatic inﬂammation,
steatosis, cholestasis, necrosis/cell death and hepatitis)
were represented in the pattern analysis.
Table 4 | Clinical characteristics and liver
biochemistries of study participants included in the
longitudinal analysis
DILI Cohort
(n = 21)
Age, mean ± s.d. (years) 52.1 ± 15.1
Female (%) 48
Self-reported race (%)
White 67
Black 14
Others 19
Unknown 0
Body mass index, mean ± s.d. (kg/m2) 27.5 ± 7.7
Alcohol use (%) 52
Preexisting liver disease (%) 14
Prior drug allergies (%) 48
Diabetes mellitus (%) 43
Liver biochemistries, mean ± s.d.
ALT (U/L)
Baseline 1325 ± 2139
6-month visit 36.1 ± 16.5
AST (U/L)
Baseline 1141 ± 1696
6-month visit 32.6 ± 11.4
Alkaline phosphatase (U/L)
Baseline 219.9 ± 161.0
6-month visit 87.2 ± 31.2
Total bilirubin (mg/dL)
Baseline 9.8 ± 9.0
6-month visit 0.9 ± 0.7
INR
Baseline 1.9 ± 1.0
6-month visit 1.1 ± 0.5
Absolute eosinophils/lL (mean ± s.d.)
Baseline 129.7 ± 132.6
6-month visit 122.2 ± 115.5
Pattern of liver injury (%)
Hepatocellular 76
Cholestatic 19
Mixed 5
Unknown 0
Severity of liver injury (%)
Mild 10
Moderate 38
Severe/fatal 29
Unknown 24
Causality score (%)
Deﬁnite 14
Very likely 43
Probable 5
Table 4 | (Continued)
DILI Cohort
(n = 21)
Possible 14
Unknown 24
Implicated agents (%)
Single prescribed agent 57
Single dietary agent 10
Multiple prescribed agents 33
Unknown 0
Chronic DILI (%) 0
Liver-related mortality (%) 0
Liver transplantation (%) 0
DILI, drug-induced liver injury; s.d., standard deviation; ALT,
alanine aminotransferase; AST, aspartate aminotransferase;
INR, international normalised ratio.
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We assessed the ability of all priority 1 proteins differ-
entially expressed between DILI patients and controls
(n = 92), along with patient characteristics (BMI and
age) and liver biochemistries (ALT, AST, alkaline phos-
phatase and bilirubin), to predict the presence of DILI.
As shown in Figure 3 (Panel B), apolipoprotein E had
the greatest diagnostic ability (89% of patients classiﬁed
correctly; AUROC = 0.97) to distinguish DILI samples
from controls. When inter-alpha-trypsin inhibitor (heavy
chain H3, isoform 1) was added, correct patient classiﬁ-
cation increased to 91% (AUROC = 0.98). Addition of
gelsolin (92% correct classiﬁcation; AUROC = 0.99)
followed by complement component C7 (93% correct
classiﬁcation; AUROC = 0.99), serum amyloid P compo-
nent (95% correct classiﬁcation; AUROC = 0.99) and
age (96% correct classiﬁcation; AUROC = 0.99) all
increased the ability to predict DILI. The ability of ALT
(73% correct classiﬁcation; AUROC = 0.99) (Figure 3;
Panel B), AST (67% correct classiﬁcation; AUROC
= 0.99), alkaline phosphatase (68% correct classiﬁcation;
AUROC = 0.96), bilirubin (77% correct classiﬁcation;
AUROC = 0.94) or all four liver biochemistries com-
bined (81% correct classiﬁcation; AUROC = 0.99) to
correctly classify patients with DILI vs. controls was also
explored.
Comparison with NAFLD proteomics
To identify potential nonspeciﬁc serum biomarkers of
liver injury, we assessed overlap of differentially
expressed priority 1 proteins identiﬁed in both the pres-
ent study of DILI patients and healthy controls (92 pri-
ority 1 proteins) and in our previous serum proteomic
study of patients across the spectrum of NAFLD and
obese controls (56 priority 1 proteins).16 Twenty-seven
priority 1 proteins exhibited signiﬁcant differential
expression (q < 0.05) compared with the respective con-
trol groups in both the DILI and NAFLD analyses, and
these proteins and their direction of change are listed in
Supplementary Table S6.
DISCUSSION
There is an important need for increased understanding
of the pathogenesis of DILI in humans. Here, we
describe results from a comprehensive serum proteomic
analysis of patients with DILI and controls. We observed
signiﬁcant differential expression of serum proteins when
comparing patients within the DILI group based on dis-
ease pattern, severity and causality assessment and iden-
tiﬁed numerous differentially expressed proteins between
DILI patients and controls. In addition, strong associa-
tions between expression levels of many priority 1 pro-
teins and liver biochemistries were detected and 53
serum proteins that changed signiﬁcantly over a 6-month
recovery period were identiﬁed. Pattern analysis of dif-
ferentially expressed proteins conﬁrmed changes in pro-
tein expression related to mechanistic pathways
previously implicated in the pathogenesis of DILI,
including inﬂammatory and acute phase response, com-
plement and coagulation system activation, and oxidative
stress.9, 24 In addition, proteins included in several hepa-
totoxicity-speciﬁc pathways were identiﬁed, including
liver inﬂammation, proliferation, steatosis/steatohepatitis/
hepatitis, cirrhosis, hepatocellular carcinoma and hepato-
cyte necrosis/death.
Large-scale ‘-omics’ technologies are powerful tools
for molecular proﬁling of complex disorders such as idi-
osyncratic DILI. Conducted primarily in animal models
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Figure 2 | Pathway analysis of priority 1 proteins with
signiﬁcant differential expression when comparing
baseline and 6-month follow-up samples from patients
with DILI included in the longitudinal analysis.
Classiﬁcation of the 53 priority 1 proteins with
signiﬁcant (q < 0.05) differential expression when
comparing patients with DILI at baseline (within
14 days of DILI onset) and after a 6-month follow-up
period revealed proteins with functions related to
inﬂammation and oxidative stress, including those
involved in liver steatosis/steatohepatitis/hepatitis and
hepatocyte necrosis/cell death. Expression of nearly all
differentially expressed proteins returned to ‘normal’
expression levels throughout the 6-month follow-up
period (using protein expression in the control group as
a reference standard).
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Figure 3 | Pathway analysis of priority 1 proteins differentially expressed between DILI patients and controls and
identiﬁcation of proteins with the greatest ability to differentiate patients with DILI vs. controls. Ingenuity Pathway
Analysis software was used to classify the 92 priority 1 proteins with signiﬁcant (q < 0.05) differential expression
when comparing DILI patients and controls (Panel A), and pattern analysis showed involvement in many pathways
previously implicated in the pathogenesis of DILI, including several directly related to hepatotoxicity (liver
inﬂammation, steatosis, cholestasis, necrosis/cell death, and hepatitis). Diagnostic power of priority 1 proteins and
clinical characteristics was explored by linear discriminant analysis and assessment of AUROC (Panel B; grey bars).
Apolipoprotein E was identiﬁed as having the greatest power to differentiate DILI patients and controls (89% of
patients classiﬁed correctly; AUROC = 0.97), and consideration of expression of several additional proteins and age
increased the percentage of patients classiﬁed correctly to 96% and the AUROC to 0.99. The diagnostic utility of ALT
alone (black bar) in differentiating patients from controls is also shown (73% correct classiﬁcation; AUROC = 0.99).
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of DILI, various proteomic studies, often supplemented
with metabonomic and transcriptomic analyses, have
revealed important information regarding prediction,
detection, pathogenesis and treatment of both acetami-
nophen-induced and idiosyncratic DILI.25–39 Of particu-
lar relevance to the current proteomic study is a report
by Andersson et al. describing metabolomic and proteo-
mic changes in serum samples from patients treated with
ximelagatran, which was associated with acute liver fail-
ure and was withdrawn from the market in 2006.30
Novel biomarkers to predict predisposition to ALT eleva-
tion and treatment response to ximelagatran were identi-
ﬁed, including apolipoproteins A-II, A-IV and E, and
subsequent hypothesis-driven in vitro studies were car-
ried out to conﬁrm previously unknown mechanisms of
toxicity. In addition, Lewis et al. utilised an innovative in
vitro model system combined with a proteomic approach
to identify intracellular and extracellular proteins
secreted into culture medium by a human hepatoma-
derived cell line (Hep G2/C3A) in response to ethanol
toxicity.27 Interestingly, several differentially expressed
proteins identiﬁed in this model system were also
detected in the current serum proteomic study, including
fructose-bisphosphate aldolase A, apolipoproteins A-I
and E, and multiple proteins involved in acute phase
and inﬂammatory responses.
In the current study, interesting associations between
expression of several identiﬁed serum proteins and liver
biochemistries were observed. For example, fumaryl-
acetoacetase, an enzyme predominantly expressed in the
liver that is essential for tyrosine metabolism, was signiﬁ-
cantly elevated in DILI patients compared with controls,
correlated with ALT, AST and alkaline phosphatase, and
was also identiﬁed as the only priority 1 protein with
signiﬁcantly higher expression in patients with hepatocel-
lular vs. mixed pattern of injury. Type I tyrosinaemia, a
genetic disorder characterised by fumarylacetoacetase
deﬁciency and systemic accumulation of tyrosine, is
strongly associated with liver failure and hepatocellular
carcinoma.40 Indeed, the signiﬁcant upregulation of fum-
arylacetoacetase expression in patients with hepatocellu-
lar DILI suggests a compensatory mechanism in
response to accumulation of tyrosine and/or other toxic
metabolites, including fumarylacetoacetate, induced by
hepatotoxic agents. Fructose-bisphosphate aldolase B, a
hepatic enzyme involved in glucose and fructose metabo-
lism, was signiﬁcantly greater in patients with DILI com-
pared with controls and in patients with hepatocellular
DILI vs. cholestatic DILI, and was identiﬁed as an inde-
pendent correlate of both serum ALT and AST eleva-
tions. Furthermore, fructose-bisphosphate aldolase B
expression was signiﬁcantly elevated at baseline and
expression returned to normal levels after 6 months in
the longitudinal analysis. These associations may provide
an explanation for the previously demonstrated detection
of serum autoantibodies to fructose-bisphosphate aldol-
ase B in patients with troglitazone-induced hepatotoxic-
ity41 and support the concept that expression levels of
this enzyme may correlate with extent of liver injury.
Identiﬁcation of useful, noninvasive biomarkers of idi-
osyncratic DILI is complicated by the fact that animal
studies predict only approximately 50% of drugs that
ultimately cause hepatotoxicity in humans, and in vitro
hepatocyte testing identiﬁes 50–60% of compounds that
can induce liver injury in human clinical trials.42 In this
serum proteomic study, we identiﬁed elevations in apoli-
poprotein E, an abundant apolipoprotein constituent of
triglyceride-rich chylomicrons and intermediate-density
lipoproteins, as having the greatest diagnostic power for
differentiating patients with DILI from controls. Interest-
ingly, Ferre et al. demonstrated that apolipoprotein E-
deﬁcient mice exhibited worse liver injury upon carbon
tetrachloride challenge compared with wild-type mice.43
Inclusion of expression of additional proteins involved in
inﬂammation [inter-alpha-trypsin inhibitor (heavy chain
H3, isoform 1) and serum amyloid P-component], mito-
chondrial stabilisation and apoptosis (gelsolin), and the
innate immune response (complement component C7
and serum amyloid P-component) increased our ability
to predict the presence of DILI. These ﬁndings are con-
sistent with the response of hepatocytes and other cell
types residing in the liver to drug-induced injury, which
involves systemic release of cytokines and other factors
implicated in various inﬂammatory and immunity path-
ways.24
Although this study was the ﬁrst to explore the global
serum proteome of patients with idiosyncratic DILI,
there are several limitations that require mention. First,
although distinguishing DILI patients from healthy con-
trol subjects is interesting from a pathogenetic stand-
point, this approach is not highly relevant in a clinical
setting. Rather, identiﬁcation of biomarkers for rapid dif-
ferentiation of patients with DILI from those with other
acute liver diseases is an important unmet clinical need.
We were unable to assess this issue as the current study
included only a small group of patients with acute liver
injury thought unlikely to be due to DILI (n = 4). Sec-
ond, a concern with multiple serum proteomic studies
involving different liver diseases is the possibility of iden-
tiﬁcation of nonspeciﬁc markers of hepatic injury. We
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compared ﬁndings from the current proteomic study in
DILI patients and healthy controls to data generated
from our previous discovery proteomic study in patients
across the spectrum of NAFLD and obese controls.16 Of
the 92 and 56 differentially expressed priority 1 proteins
identiﬁed in the DILI and NAFLD analyses respectively,
only 27 common proteins were identiﬁed and may serve
as general biomarkers of liver injury. Importantly, apoli-
poprotein E, which was identiﬁed as having the greatest
ability to differentiate DILI patients from controls, was
not differentially expressed in the NAFLD proteomic
analyses. This protein, along with the additional 65 pro-
teins with signiﬁcant differential expression unique to
the DILI analysis, may serve as candidate biomarkers for
identiﬁcation of DILI. Third, we were unable to assess
changes in serum protein expression with regard to indi-
vidual medications/supplements due to the large number
of agents and small numbers of patients exposed to indi-
vidual drugs. Finally, prediction of individuals who will
go on to develop hepatotoxicity prior to drug exposure
would be an invaluable tool for drug development and
improved patient safety. This type of analysis requires
serum samples taken prior to DILI onset, which are not
available as part of the DILIN prospective registry.
Despite these limitations, our study provides novel
insight into changes in the serum proteome in patients
with idiosyncratic drug-induced hepatotoxicity and pro-
vides a foundation for future hypothesis-driven studies
that may aid in prevention, early detection, clariﬁcation
of pathogenesis and effective treatment modalities for
DILI.
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